Easton Pharmaceuticals Inc. (OTCPK:EAPH) signed a letter of intent to acquire iBliss Inc. on January 23, 2017. The iBliss acquisition is intended to have iBliss operate as a wholly owned subsidiary of Easton Pharmaceuticals and will be separate from Easton Pharmaceuticals's other business segments. The definitive agreement is to be finalized in the coming weeks. As of April 11, 2017, Easton Pharmaceuticals announces all terms of the acquisition agreement to acquire iBliss were finalized. As on April 20, 2017, Terms of the acquisition included installment cash payments to be paid over a 90 day period with the first payment submitted on closing and up to 200 Million restricted Rule 144 shares in Easton's common stock, to be released in tranches based on sales target milestones.